

LifeSci Biotechnology Clinical Trials Index
LifeSci Biotechnology Products Index
Removal of Component(s) – RXDX, JUNO, BIVV
2/6/2018

Effective at the market close on Thursday, February 8, 2018, **RXDX and JUNO** will be removed from the **LifeSci Biotechnology Clinical Trials Index** and their combined values will be redistributed to the remaining index components based on their weights.

- On 12/22/2017, Ignyta (RXDX) announced that it will be acquired by Roche for \$27 per share in cash.
- On 1/22/2018, Juno Therapeutics (JUNO) announced that it will be acquired by Celgene for \$87 per share in cash.

Effective at the market close on Thursday, February 8, 2018, **BIVV** will be removed from the **LifeSci Biotechnology Products Index** and its value will be redistributed to the remaining index components based on their weights.

- On 1/22/2018, Bioverativ (BIVV) announced that it will be acquired by Sanofi for \$105 per share in cash.